OvaScience (NASDAQ: OVAS) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare OvaScience to related businesses based on the strength of its dividends, analyst recommendations, profitability, earnings, institutional ownership, risk and valuation.
This is a summary of current ratings and target prices for OvaScience and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
55.1% of OvaScience shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 9.5% of OvaScience shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
OvaScience has a beta of 3.73, indicating that its stock price is 273% more volatile than the S&P 500. Comparatively, OvaScience’s peers have a beta of 1.57, indicating that their average stock price is 57% more volatile than the S&P 500.
Valuation and Earnings
This table compares OvaScience and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|OvaScience Competitors||$217.36 million||-$39.57 million||-64.98|
OvaScience’s peers have higher revenue and earnings than OvaScience. OvaScience is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares OvaScience and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
OvaScience peers beat OvaScience on 8 of the 13 factors compared.
OvaScience Company Profile
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.
What are top analysts saying about OvaScience? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for OvaScience and related companies.